Frontline Inotuzumab Ozogamicin with Low-intensity Chemotherapy (mini-hyper-CVD) in Older Patients with Acute Lymphoblastic Leukemia (ALL): Updated Results of a Phase I/II Trial
Older patients with ALL are often intolerant to intensive chemotherapy and have poor outcomes. We hypothesized that combination of low-intensity chemotherapy with anti-CD22 antibody-drug conjugate inotuzumab ozogamicin (InO) may improve outcomes in the frontline setting.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Abhishek Maiti, Hagop Kantarjian, Susan O'Brien, Farhad Ravandi, Nicholas Short, Deborah Thomas, Guillermo Garcia-Manero, Naval Daver, Gautam Borthakur, Nitin Jain, Marina Konopleva, Koji Sasaki, Naveen Pemmaraju, Yesid Alvarado, Jovitta Jacob, Rebecca Ga Source Type: research
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Chemotherapy | Leukemia | Lymphoma | Myeloma